| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
-cell function in non-diabetic subjects at high risk for type 2 diabetes
1 Endocrinology, University of Arkansas for Medical Sciences and Central Arkansas Veterans Healthcare System, Little Rock, Arkansas, United States
2 Obstetrics and Gynecology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
3 Little Rock, Arkansas, United States; Endocrinology, University of Arkansas for Medical Sciences and Central Arkansas Veterans Healthcare System, Little Rock, Arkansas, United States
* To whom correspondence should be addressed. E-mail: rasoulineda{at}uams.edu.
Thiazolidinediones (TZDs) and metformin decreased the incidence of diabetes in subjects at risk for developing diabetes by enhancing insulin sensitivity. Whether they also directly improved 
-cell function is not clear. In vitro studies showed improved -cell function in response to TZDs and metformin, however, the effects of TZDs or metformin on -cell function in humans are still uncertain.
We hypothesized that both TZDs and metformin directly affect -cell function. We evaluated -cell function and insulin sensitivity (SI) in subjects with impaired glucose tolerance or a history of gestational diabetes using oral and intravenous glucose tolerance tests in addition to the glucose potentiated arginine stimulation test.
In contrast to metformin, pioglitazone improved SI, glucose tolerance and insulin independent glucose disposal (SG). Neither pioglitazone nor metformin significantly improved -cell compensation for insulin resistance (DI) but the change in DI significantly correlated with baseline SI. Insulin secretion in response to arginine at maximally potentiating glucose levels (AIRmax) tends to increase after metformin and to decrease after pioglitazone; however, when adjusted for SI, the changes were not significant.
Our results demonstrate that in non-diabetic subjects at risk for diabetes, pioglitazone but not metformin significantly improved glucose tolerance by improving SI and SG. We did not find any evidence that either pioglitazone or metformin improved -cell function. Improved -cell compensation was observed primarily in the subgroup of subjects who had the lowest SI at baseline.
This article has been cited by other articles:
|
|
 |
|
  N. Rasouli, A. Yao-Borengasser, V. Varma, H. J. Spencer, R. E. McGehee Jr, C. A. Peterson, J. L. Mehta, and P. A. Kern Association of Scavenger Receptors in Adipose Tissue With Insulin Resistance in Nondiabetic Humans Arterioscler Thromb Vasc Biol, September 1, 2009; 29(9): 1328 - 1335. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Zhang, D. Dey, R. Branstrom, L. Forsberg, M. Lu, Q. Zhang, and A. Sjoholm BLX-1002, a novel thiazolidinedione with no PPAR affinity, stimulates AMP-activated protein kinase activity, raises cytosolic Ca2+, and enhances glucose-stimulated insulin secretion in a PI3K-dependent manner Am J Physiol Cell Physiol, February 1, 2009; 296(2): C346 - C354. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. K. Das, W. S. Chu, A. K. Mondal, N. K. Sharma, P. A. Kern, N. Rasouli, and S. C. Elbein Effect of pioglitazone treatment on endoplasmic reticulum stress response in human adipose and in palmitate-induced stress in human liver and adipose cell lines Am J Physiol Endocrinol Metab, August 1, 2008; 295(2): E393 - E400. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R.-R. Wu, J.-P. Zhao, H. Jin, P. Shao, M.-S. Fang, X.-F. Guo, Y.-Q. He, Y.-J. Liu, J.-D. Chen, and L.-H. Li Lifestyle Intervention and Metformin for Treatment of Antipsychotic-Induced Weight Gain: A Randomized Controlled Trial JAMA, January 9, 2008; 299(2): 185 - 193. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Visit Other APS Journals Online |
